Immunotherapy with chimeric antigen receptors for multiple myeloma

Area of Science:

• Immunotherapy
• Oncology
• Cellular Therapy

Background:

• Chimeric antigen receptors (CARs) redirect T cells to target cancer cells.
• CAR T cell therapy has shown success in B cell malignancies.
• Multiple myeloma is a hematologic malignancy with unmet treatment needs.

Purpose of the Study:

• To review the development of CAR T cell therapies for multiple myeloma.
• To highlight current and upcoming clinical trials for CARs in multiple myeloma.
• To discuss the potential future applications of CAR T cell therapy in multiple myeloma treatment.

Main Methods:

• Review of ongoing clinical trials and pre-clinical research for CARs in multiple myeloma.
• Identification of target antigens for CAR development in multiple myeloma (Kappa light chain, CD138, Lewis Y, BCMA, CS1, CD38).

Main Results:

• Clinical trials are active for CARs targeting Kappa light chain, CD138, and Lewis Y antigen.
• CARs targeting BCMA, CS1, and CD38 are in pre-clinical development.
• Early trials focus on relapsed/refractory multiple myeloma.

Conclusions:

• CAR T cell therapy is a promising avenue for multiple myeloma treatment.
• Further research and clinical trials are essential to optimize CAR therapy for multiple myeloma.
• CAR T cell therapy may be used as consolidation or in combination with other treatments.